Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial (PL02.004)

Merit Cudkowicz; Leonard Van den Berg; Jeremy Shefner; Hiroshi Mitsumoto; Jesus Mora; Albert Ludolph; Orla Hardiman; Evan Ingersoll; Donald Archibald; Adam Meyers; Yingwen Dong; Wildon Farwell; Douglas Kerr

doi:10.1212/WNL.80.7_supplement.PL02.004

Back

Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial (PL02.004)

Journal article

Peer reviewed

Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial (PL02.004)

Merit Cudkowicz, Leonard Van den Berg, Jeremy Shefner, Hiroshi Mitsumoto, Jesus Mora, Albert Ludolph, Orla Hardiman, Evan Ingersoll, Donald Archibald, Adam Meyers, …

Neurology, Vol.80(7_supplement)

02/12/2013

DOI: https://doi.org/10.1212/WNL.80.7_supplement.PL02.004

Metrics

1 Record Views

Details

Title: Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial (PL02.004)
Creators: Merit Cudkowicz - MGH MDA ALS Clinic Charlestown MA
Leonard Van den Berg - University Medical Center Utrecht
Jeremy Shefner - SUNY Upstate Medical University
Hiroshi Mitsumoto - Columbia University Irving Medical Center
Jesus Mora - Hospital Carlos 111 Madrid Spain
Albert Ludolph - Universität Ulm
Orla Hardiman - Beaumont Hospital
Evan Ingersoll - Knopp Biosciences (United States)
Donald Archibald - Knopp Biosciences (United States)
Adam Meyers - Biogen (United States)
Yingwen Dong - Biogen (United States)
Wildon Farwell - Biogen (United States)
Douglas Kerr - Biogen (United States)
Publication Details: Neurology, Vol.80(7_supplement)
Identifiers: 991006262269002656
Academic Unit: Neurology
Language: English
Resource Type: Journal article

Efficacy of Dexpramipexole in Amyotrophic Lateral Sclerosis: Data from the Phase III EMPOWER Trial (PL02.004)

Related links

Metrics

Details